Navigation Links
New Techniques Use Lasers, LEDs, and Optics to ‘See’ Under the Skin
Date:7/18/2013

es are imaging blood flow and analysis of the wound healing processes.

Ten of the special section’s 31 papers are available via open access in the SPIE Digital Library. Among the open access papers are reports on:

  •      Non-contact imaging to assess pulse rate, by Yu Sun of Singapore Institute for Neurotechnology and researchers at Loughborough University and Barts and the London School of Medicine and Dentistry
  •     In vivo imaging to detect skin cancer, by Lioudmila Tchvialeva and others at Vancouver Coastal Health Research Institute, University of British Columbia, BC Cancer Agency, and Simon Fraser University
  •     Nanoparticle drug delivery through skin, by Leshuai Zhang and Nancy Monteiro-Riviere of Kansas State University
  •     Non-contact optical assessment of skin burn, by Ryosuke Tanaka and other researchers from several departments at Osaka University and from Nara Medical University and University of Tokushima
  •     Non-invasive diagnosis of wound healing, by Gitanjal Deka and other researchers at National Yang-Ming University and Taipei City Hospital.

Journal of Biomedical Optics Editor-in-Chief is Lihong Wang, Gene K. Beare Distinguished Professor of Biomedical Engineering at Washington University in St. Louis.

SPIE Digital Library articles are available via subscription or pay-per-view. The SPIE Digital Library contains more than 325,000 articles from SPIE journals, proceedings, and books, with approximately 18,000 new research papers a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
2. BioTechniques Announces the Publication of 'Transfection' – The First Issue of a New, Digital-Only Spotlight Series
3. New measuring techniques can improve efficiency, safety of nanoparticles
4. ResearchMoz: Vaccine Production Market (Trends, Techniques, Key Players, Spending Estimates and Forecasts)
5. UKA Optics Adds to Its Existing Line of Quartz Lenses, a 6mm F/3.5 UV Lens with Locking Focus and Iris
6. ICO Honors Three with Awards during SPIE Optics and Optoelectronics
7. See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics
8. TrueVision® 3D Surgical and i-Optics Announce Collaboration to Integrate Diagnostics and Computer-Guidance in Cataract Surgery
9. Leading Photonics and Laser Researchers to Present Latest Work at SPIE Optics + Optoelectronics
10. The ‘Cooke Look’: SPIE Congratulates Optics Firm on Oscar for Well-loved Lens Technology
11. Fujimoto Honored with Britton Chance Biomedical Optics Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... BRAINTREE, Mass. , May 20, 2015  Haemonetics ... Brian Concannon , President & CEO, will present at ... New York on June 1 st , ... public may access Mr. Concannon,s presentation live via webcast ... Haemonetics Haemonetics (NYSE: HAE ) is a ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... , DALLAS, July 23 ... S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) ... collecting data from a post approval study of MuGard in head and neck cancer ... a multi-center study expected to enroll a total of 280 patients, patients are provided ...
... , , ST. LOUIS, July ... Science and High Technology company, reported second quarter 2009 diluted EPS ... For the six months ended June 30, 2009, reported diluted ... the first six months of 2008. Excluding the negative impact ...
... , , SEATTLE, July 23 ... today announced the pricing of an underwritten public offering of 29,332,107 ... 7,333,027 shares of its common stock at a price to the ... purchase 0.25 shares of common stock, for gross proceeds of approximately ...
Cached Biology Technology:MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 2Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 4Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 5Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 6Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 7Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 8Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 9Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 10Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 11Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 12Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 13Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 14Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 15Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 16Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 17Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Today, the country,s leading health technology company, ... $15 million in new funding. This extension funding, led ... Ventures, brings Practice Fusion,s Series D funding to $85 ... million. The round was co-led by Longitude Capital, a ...
... (Dec. 9, 2013) For nearly half a century, ... ocular drug delivery that may someday replace eye drops, ... challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School ... Institute of Technology are one step closer to an ...
... gene that drives the development of tumours in over one ... time that the gene CUX1 has been broadly linked to ... deactivated, a biological pathway is activated that increases tumour growth. ... in the clinic and are in development thus highlighting a ...
Cached Biology News:Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month 2Gene promotes 1 in 100 of tumors 2